Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer

NCT01409005 | Completed Phase 2

• 1 other identifier: CRC-SNU-2011-01
• Study Type: interventional
• Target: 41
• Locations: 1 country
• Sites: 3

Brief Summary

Although there have been remarkable advances in the treatment of metastatic or recurrent colorectal cancer (MRCRC), long term survival cannot be expected in most patients with MRCRC because of inevitably developing resistance to chemotherapeutic drugs except some MRCRC patients who can undergo complete resection (metastasectomy). Until now, approved cytotoxic drugs for treatment of MCRC are only 3 categories (fluoropyrimidine, oxaliplatin and irinotecan). Recently, molecularly targeted drugs are approved for MRCRC patients, and bevacizumab and cetuximab (for K-ras wild type tumors) are available. When cytotoxic and targeted drugs are appropriately combined, about 24 months of overall survival (OS) can be expected in patients with MRCRC. However, when these drugs are all used or patients cannot afford to receive expensive targeted drugs because of economical problems, there is no option for chemotherapy and best supportive care is the only option, although some patients still have good performance status and medical conditions. Therefore, there are unmet needs for additional salvage chemotherapy regimens for patients with oxaliplatin, irinotecan and fluoropyrimidine-refractory MRCRC. In some previous studies, gemcitabine-based chemotherapy showed some antitumor activities in MRCRC patients. Especially, when combined with fluoropyrimidine, gemcitabine has been shown to exert synergic effects on antitumor activities. On these backgrounds, this phase 2 clinical study was designed. In this study, efficacy and safety of gemcitabine plus UFTE chemotherapy will be evaluated in MRCRC patients.

Conditions

Metastatic or Recurrent Colorectal Cancer; Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan; Salvage Chemotherapy

Outcome Measures

Primary Outcomes (1)

• 8-weeks progression free survival rate (PFS rate)

  % of patients without tumor prgression at 8 weeks after the initiation of chemotherapy

  Response evaluation using computed tomography (CT) at 8 weeks after the initiation of chemotherapy

Secondary Outcomes (3)

• Overall survival (OS)

  OS will be measured until death or study completion, with an expected average of 9 months

• Response rate (RR)

  Response evaluation using CT will be performed every 8 weeks until tumor progression or death

• Percentage of Patients with Adverse Events

  Overall safety will be monitored on every visit of patients during chemotherapy, with an expected average of 4 months

Study Arms (1)

Gemcitabine plus UFTE

EXPERIMENTAL

Gemcitabine plus UFTE chemotherapy (Single arm)

Drug: Gemcitabine and UFTE chemotherapy

Interventions

Gemcitabine and UFTE chemotherapy DRUG

Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15 UFTE : 200mg/m2 PO q 8 hr, Days 1\~21 Interval: every 4 weeks

Gemcitabine plus UFTE

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: ≥ 18 years old
• ECOG performance status: 0 to 2
• Pathologically proven adenocarcinoma of colorectum
• Patients who had received all cytotoxic drugs of 3 categories (fluoropyrimidine \[5-FU, capecitabine or S-1 etc.\], oxaliplatin and irinotecan).
• Refractory MRCRC that progressed while receiving, or within 6 months after the discontinuation of all of fluoropyrimidine, oxaliplatin and irinotecan. When retry of fluoropyrimidine, oxaliplatin or irinotecan is not possible due to previous severe toxicities despite progression-free interval ≥ 6 months, patients can be enrolled into this study.
• Patients who were previously treated with cetuximab or to whom cetuximab cannot be used (i.e. K-ras mutant or economical problems)
• At least one measurable lesion should exist (RECIST version 1.1)

You may not qualify if:

• Patients who had not previously received all of fluoropyrimidine, oxaliplatin and irinotecan will be excluded.
• Patients who had received UFTE chemotherapy previously. However, if UFTE chemotherapy was used as adjuvant chemotherapy and the disease-free interval was greater than 6 months, the patient can be included into this study.
• Patients receiving active or passive immunotherapy
• Patients with complete bowel obstruction or progressive symptoms of partial bowel obstruction that interfere with adequate oral diet.
• Patients with large amount of ascites requiring frequent therapeutic paracentesis (\> once per week)
• Pregnant or breast-feeding women (a pregnancy test must be performed on all female patients who are of child-bearing potential before entering the study)
• Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period. Sexually active fertile men not using effective birth control during the study if their partners are women of child-bearing potential
• Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy (i.e., uncontrolled infection, uncontrolled epilepsy, cerebrovascular accidents within the past 6 months, neurologic or psychological disease interfering with study treatment)
• Inadequate cardiovascular function:
• New York Heart Association class III or IV heart disease,
• Unstable angina or myocardial infarction within the past 6 months,
• Symptomatic coronary artery disease
• History of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality
• Symptomatic severe interstitial lung disease or pulmonary fibrosis
• Patients with impaired renal function: Creatinine clearance \< 50mL/min (calculated by Cockcroft and Gault formula)

Sponsors & Collaborators

• Seoul National University Bundang Hospital: lead
• Seoul National University Hospital: collaborator
• SMG-SNU Boramae Medical Center: collaborator
• Yuhan Pharmaceutical Company: collaborator
• Jeil Pharmaceutical Company: collaborator

Study Sites (3)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 463-707, South Korea

Location

Seoul National University Hospital

Seoul, Seoul, South Korea

Location

SMG-SNU Boramae Medical Center

Seoul, Seoul, South Korea

Location

MeSH Terms

Conditions

Neoplasm Metastasis; Colorectal Neoplasms

Interventions

Gemcitabine

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring

Study Officials

• Jee Hyun Kim, M.D. & Ph.D.

  Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: July 29, 2011
• First Posted: August 3, 2011
• Study Start: June 1, 2011
• Primary Completion: February 1, 2013
• Last Updated: February 11, 2014

Record last verified: 2014-01

Locations

KR (3)